Physician profile
Stephen H Pollock
NPI 1982698973
$11,175.91
in general payments reported to CMS, 2019-2025
40 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,160 · 2020: $649 · 2021: $950 · 2022: $2,056 · 2023: $2,019 · 2024: $2,056 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,361.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,104.73 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,093.85 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,009.22 | 2019-2025 | Jardiance |
| Medtronic, INC. | $922.54 | 2021-2025 | Onyx Frontier, Micra, Symplicity G3 |
| Edwards Lifesciences Corporation | $890.60 | 2019-2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $841.97 | 2019-2024 | Xarelto |
| Amgen INC. | $716.40 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $712.18 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $434.88 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $339.44 | 2019-2024 | |
| Amarin Pharma, INC. | $338.36 | 2019-2023 | |
| Novo Nordisk INC | $313.97 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $293.63 | 2019-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $225.06 | 2022-2025 | Amvuttra, Onpattro |
| Esperion Therapeutics, INC. | $207.03 | 2020-2025 | Nexletol |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $174.87 | 2022-2024 | Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit, Tendril |
| Atricure, INC. | $162.04 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $156.30 | 2023-2025 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals, LTD. | $132.24 | 2022-2023 | Arcalyst |
| Philips North America LLC | $103.78 | 2020-2024 | (5091) Amb Mon & Diag Und |
| Boston Scientific Corporation | $95.75 | 2023-2024 | Watchman, Watchman Access System, Resonate El Icd Vr |
| Merck Sharp & Dohme LLC | $91.50 | 2022-2024 | Verquvo |
| Gilead Sciences, INC. | $91.47 | 2019 | |
| Irhythm Technologies, INC. | $85.67 | 2019-2024 | Zio Monitor, Zio Xt Patch |
| Kiniksa Pharmaceuticals International, Plc | $79.09 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $69.82 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $63.24 | 2025 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $49.77 | 2019 | |
| Preventice Services, LLC | $45.60 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $39.77 | 2020-2021 | |
| Braemar Manufacturing, LLC | $36.46 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.03 | 2023 | |
| Heartflow, INC. | $35.36 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $35.11 | 2023 | Inpefa |
| Baxter Healthcare | $32.20 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Biotronik INC. | $30.22 | 2019-2021 | |
| Cardiva Medical, INC. | $29.38 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Medtronic Vascular, INC. | $27.73 | 2019 | |
| Itamar Medical INC | $18.62 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $10.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Pollock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.